Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

Vaginal Cancer Clinical Trial

Official title:

Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05027776
• Other study ID #: 4-HPV-3002
• Status: Recruiting
• Phase: Phase 3
• Start date: September 15, 2021
• Est. completion date: September 29, 2026

Study information

• Verified date: April 2024
• Source: Shanghai Bovax Biotechnology Co., Ltd.
• Contact: Ting Huang
• Phone: 86-13330993324
• Email: cocoht[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years

Description:

This is a singel-center study (protocol 4-HPV-3002) in which women are planned to receive q-HPV vaccine. Study participation will last approximately 60 months and involves a total of nine or eleven scheduled visits.

This study will also assess whether the immunogenicity of the q-HPV vaccine given 2-dose schedule in 9-14 year old girls is noninferior to that in young women, aged 20-26, receiving 3 doses, and 3 doses in 9-19 year old girls is noninferior to that in young women receiving 3 doses, while assessing the safety of this vaccine.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1348
• Est. completion date: September 29, 2026
• Est. primary completion date: November 22, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 9 Years to 26 Years

Eligibility

Inclusion Criteria:

1. Healthy Chinese females aged 9 to 26 years; Provide legal identification;

2. The subject voluntarily agrees to enroll in this study. If the subject is a minor, both the subject and subject's legal guardian should voluntarily agree to enroll in this study and sign an informed consent form;

3. Had a negative urine pregnancy test on the day of enrollment, among the subjects of childbearing age; Not in the duration of breast-feeding and no birth plan within 7 months; According to the investigator's judgment that there is no possibility of pregnancy at that time: subjects have taken effective contraception, or asexual life after the last menstrual period, or use IUD, or had undergone ligation; subjects agree to continue take effective contraception such as taking OCS and condom use;

4. No fever symptoms on the day of enrollment (aged> 14 years old, axillary temperature<37.3°C; aged = 14 years old, axillary temperature<37.5°C );

5. Be able to understand the study procedures and promise to participate in regular follow-ups under the requirements;

Exclusion Criteria:

1. Received marketed HPV vaccine or plan to receive marketed HPV vaccine during this study period or have enrolled in HPV vaccine clinical trials;

2. Enrolling or plan to enroll in other clinical trials (drug or vaccine);

3. History of positive test to HPV, history of cervical cancer (e.g. abnormal screening test results, abnormal cervical biopsy results, including CIN, LSIL, and cervical cancer) or history of pelvic radiotherapyherpes;

4. History of diseases related to HPV infection (e.g. genital warts, VIN, VaIN, and related cancers) or history of STDs, including syphilis, gonorrhea, genital herpes, Mycoplasma genitalium, Lymphgranuloma Venereum, granuloma inguinale, etc.;

5. Known allergy to any vaccine components or history of severe allergic diseases requiring treatment, including shock, laryngeal edema, urticarial, Henoch-Schonlein purpura, Arthus reaction, etc.;

6. Had primary or acquired immunodeficiency such as HIV, SLE, JRA, etc;

7. History of epilepsy and convulsions (except fever convulsions in children under 5 years of age);

8. Subjects with existing infectious diseases such as TB, viral hepatitis, and/or HIV infection; or existing liver or kidney conditions, CVDs, and malignancy;

9. Untreated/uncontrolled hypertension before vaccination (aged 9 to 17 years: systolic BP=120mmHg and/or diastolic BP=80mmHg; aged more than 18 years: Systolic BP=140mmHg and/or diastolic BP =90mmHg);

10. With prohibitive contraindications such as Thrombocytopenia or coagulopathy;

11. Asplenic, functionally asplenic, or splenectomy caused by any condition;

12. Received immunosuppressive treatment within one month before study such as long-term glucocorticoid use(=2mg per kg per day, lasted more than two wks), or plan to receive such treatment from month 0 to month 7;

13. Receipt of immune globulin or blood-related products within 3 months; or plan to receive such products during this study period(month 0 to month 7);

14. Within 3 days prior to vaccination, have an acute disease or are in the acute attack of a chronic disease or have used antipyretic, analgesic and anti-allergic drugs (such as: acetaminophen, ibuprofen, aspirin, loratadine, ceti Rizine, etc.);

15. Receipt of inactivated, RNA, and recombinant vaccines within 14 days, live vaccines within 28 days;

16. Subjects with existing mental illness, History of mental illness, or Family History;

17. According to the investigator's judgment, the subject has any condition may interfere with process of evaluation or participating in this study cannot guarantee the object's maximum benefit.

Related Conditions & MeSH terms

• Cervical Cancer Stage IIa
• CIN1
• CIN2
• CIN3
• Condylomata Acuminata
• Genital Wart
• HPV Infections
• Papillomavirus Infections
• Uterine Cervical Neoplasms
• Vaginal Cancer
• Vaginal Neoplasms

Intervention

Biological:
• 2-doses Group among 9-14 years
Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.
• 3-doses Group among 9-19 years
Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
• 3-doses Group among 20-26 years
Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.

Locations

Country	Name	City	State
China	Center for Disease Control and Prevention	Mianyang	Sichuan

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Bovax Biotechnology Co., Ltd.	Chongqing Bovax Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary immunogenicity outcome	Number of subjects receiving the whole schedule vaccination with antibody responses as assessed by GMT and SCR, change from baseline among the seronegative vaccine recipients at Month 8	At month 8
Secondary	Secondary immunogenicity outcome	TNumber of subjects, aged 9 to 14, receiving the 2-doses scheduled vaccination with antibody responses as assessed by GMT and SCR, change from baseline among the seronegative vaccine recipients at Month 12, 24, 36, 48 and 60	At month 12, 24, 36, 48 and 60
Secondary	Number of subjecs with AEs	Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, fever (= axillary temperature above 37.3°C or 37.5°C) and urticaria.	Within 30 minutes (Days 0) after vaccination
Secondary	Numbers of subjects with solication of AEs	Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, fever (= axillary temperature above 37.3°C or 37.5°C) and urticaria.	Within 8 days (Days 0-8) after vaccination
Secondary	Numbers of subjects with unsolicited AEs	An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.	Within days 0-30 after vaccination
Secondary	Number of subjects receiving the whole schedule vaccination with SAEs	SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.	Subjects receiving a 2-doses shceduled vaccination from Day o to Month 60; Subjects receiving a 3-doses shceduled vaccination from Day o to Month 12
Secondary	Number of subjects with pregnancy events	Outcomes of pregnancies were Live infant NO apparent congenital anomaly (ACA) , Live infant, Elective termination NO ACA, Elective termination CA, Ectopic pregnancy, Spontaneous abortion NO ACA, Stillbirth NO ACA, Stillbirth CA, Lost to follow up and Pregnancy ongoing.	Subjects receiving a 2-doses shceduled vaccination from Day o to Month 60; Subjects receiving a 3-doses shceduled vaccination from Day o to Month 12